Search results for " severity of illness"

showing 4 items of 104 documents

Severe asthma at COVID-19 time: what is new on biologic therapies.

2021

medicine.medical_specialty2019-20 coronavirus outbreakAsthma therapyCoronavirus disease 2019 (COVID-19)business.industrySevere asthmaBiologic therapiesMEDLINECOVID-19General MedicineSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaseSeverity of Illness IndexAsthmaAsthma; COVID-19; Humans; Severity of Illness Index; Biological TherapyBiological TherapyInternal medicineSeverity of illnessmedicineHumansbusinessAsthmaHumanMinerva medica
researchProduct

Restoring Neurological Physiology: The Innovative Role of High-Energy MR-Guided Focused Ultrasound (HIMRgFUS). Preliminary Data from a New Method of …

2017

Background Tremor is a disabling condition, common to several neurodegenerative diseases. Lesioning procedures and deep brain stimulation, respectively, of the ventralis intermedius nucleus for intentional tremor, and of the subthalamic nucleus for parkinsonian resting tremor, have been introduced in clinical practice for patients refractory to medical treatment. The combination of high-energy focused ultra-sound (HIFUS) with sophisticated magnetic resonance (MR) instrumentation, together with accurate knowledge of the stereotactic brain coordinates, represents a revolution in neuromodulation. Methods At the Neurosurgical Clinic and the Radiology Department of the University of Palermo,, tw…

medicine.medical_specialtyParkinson's diseaseDeep brain stimulationmedicine.medical_treatmentNeurosurgical ProcedureSeverity of Illness IndexNeurosurgical ProceduresFocused ultrasoundMRI-guided focused ultrasound (MRgFUS)03 medical and health sciences0302 clinical medicineTremormedicineHumans030212 general & internal medicineResting tremorVentral Thalamic Nucleimedicine.diagnostic_testEssential tremorSettore MED/27 - Neurochirurgiabusiness.industryEssential tremor; functional neurosurgery; lesioning surgery; MRI-guided focused ultrasound (MRgFUS); Parkinson’s disease; brain; high-intensity focused ultrasound ablation; humans; magnetic resonance imaging; neurosurgical procedures; severity of illness index; surgery computer-assisted; tremor; ventral thalamic nucleiSettore MED/37 - NeuroradiologiaBrainMagnetic resonance imagingLesioning surgerymedicine.diseaseMagnetic Resonance ImagingNeuromodulation (medicine)nervous system diseasesSurgerySubthalamic nucleusFunctional neurosurgerySurgery Computer-AssistedParkinson’s diseaseEssential tremorHigh-Intensity Focused Ultrasound AblationSettore MED/36 - Diagnostica Per Immagini E Radioterapiabusiness030217 neurology & neurosurgeryHuman
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct